Susan G. Komen for the Cure Statement on FDA's Decision Removing Genentech's Avastin from Approved Breast Cancer Drugs

Published: Nov 18, 2011

DALLAS--(BUSINESS WIRE)--Susan G. Komen for the Cure®, the world’s largest breast cancer organization, issued the following statement today from Komen president Elizabeth Thompson about the U.S. Food and Drug Administration’s decision removing Avastin from the list of approved drugs for the treatment of advanced and metastatic breast cancer:

Back to news